Zymeworks Inc. (NASDAQ:ZYME) Targets Significant Growth with Promising Drug Development
Zymeworks(US:ZYME) Financial Modeling Prepยท2025-11-18 04:10Andrew Berens from Leerink Partners set a price target of $37 for NASDAQ:ZYME, indicating a potential increase of approximately 54.81%.Ziihera, developed in collaboration with Jazz Pharmaceuticals, shows significant improvement in treating HER2-positive gastroesophageal adenocarcinoma.ZYME's market capitalization stands at approximately $1.8 billion, with a trading volume of 11.1 million shares, reflecting increased investor interest.Zymeworks Inc. (NASDAQ:ZYME) is a biotechnology company focused on develop ...